This week on CLL Society (http://cllsociety.org) in our 2015 conference coverage (http://cllsociety.org/conference-coverage/2015-conferences/) section, we feature an interview with me by fellow CLL patient, Carol Preston of Patient Power (http://www.patientpower.info) where I quickly outline my take on three papers from ASCO 2015 on CLL.
ASCO is more about solid cancers, so the news on CLL tends to be scarce.
The three presentations are on a new prognostic scale, on a new non-chemo triplet therapy and finally on Bendamustine with and without ibrutinib.
In the accompanying text, I go into more detail, and of course provide a link to the source material itself so we can all form our own opinions.
Your comments are welcome.
I am off to iwCLL 2015 in a few weeks where I will be speaking on a panel with Dr. Keating and others on how to improve access to expensive cancer medications. I also plan to meet other CLL patients and interview the experts gathered in Sydney, Australia.
We are all in this together.